<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus" exact="disease" post="2019 Di CosimoSerenaaMalfettoneAndreabPÃ©rez-GarcÃ­aJosÃ© M.bcLlombart-CussacAntoniobdMiceliRosalbaeCuriglianoGiuseppefgCortÃ©sJavierjacortes@vhio.netbchâˆ—[a], [b], [c], [d], [e], [f],"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="remains active. Abstract While confirmed cases of the deadly coronavirus" exact="disease" post="2019 (COVID-19) have exceeded 4.7 million globally, scientists are"/>
 <result pre="their complications currently exist, the rapidly expanding knowledge regarding severe" exact="acute" post="respiratory syndrome coronavirus 2 and its interplay with hosts"/>
 <result pre="complications currently exist, the rapidly expanding knowledge regarding severe acute" exact="respiratory" post="syndrome coronavirus 2 and its interplay with hosts provides"/>
 <result pre="currently exist, the rapidly expanding knowledge regarding severe acute respiratory" exact="syndrome" post="coronavirus 2 and its interplay with hosts provides a"/>
 <result pre="of immune checkpoint inhibitors that have been recently tested beyond" exact="cancer" post="treatment for their potential to restore cellular immunocompetence. Highlights"/>
 <result pre="potential to restore cellular immunocompetence. Highlights â€¢Patients with severe coronavirus" exact="disease" post="2019 (COVID-19) present with lymphocytopenia and T-cell exhaustion. â€¢Persistent"/>
 <result pre="present with lymphocytopenia and T-cell exhaustion. â€¢Persistent stimulation by severe" exact="acute" post="respiratory syndrome coronavirus 2 leads to the inhibition of"/>
 <result pre="with lymphocytopenia and T-cell exhaustion. â€¢Persistent stimulation by severe acute" exact="respiratory" post="syndrome coronavirus 2 leads to the inhibition of the"/>
 <result pre="lymphocytopenia and T-cell exhaustion. â€¢Persistent stimulation by severe acute respiratory" exact="syndrome" post="coronavirus 2 leads to the inhibition of the immune"/>
 <result pre="inhibition of the immune system. â€¢Immune blockade in patients with" exact="cancer" post="supports host protective immunity. â€¢Immune checkpoint inhibitors safely restore"/>
 <result pre="immunity. â€¢Immune checkpoint inhibitors safely restore immunocompetence in sepsis and" exact="viral" post="infections. â€¢Immunostimulants should be considered as the first-line option"/>
 <result pre="Keywords COVID-19 SARS-CoV-2 Cytokine storm Antiâ€&quot;PD-1 Antiâ€&quot;IL-6R Pembrolizumab Tocilizumab Coronavirus" exact="disease" post="2019 (COVID-19) is a pandemic infection caused by a"/>
 <result pre="Antiâ€&quot;IL-6R Pembrolizumab Tocilizumab Coronavirus disease 2019 (COVID-19) is a pandemic" exact="infection" post="caused by a positive-sense RNA betacoronavirus named severe acute"/>
 <result pre="pandemic infection caused by a positive-sense RNA betacoronavirus named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome"/>
 <result pre="infection caused by a positive-sense RNA betacoronavirus named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS)"/>
 <result pre="caused by a positive-sense RNA betacoronavirus named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) and"/>
 <result pre="RNA betacoronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)." exact="Acute respiratory distress syndrome" post="(ARDS) and multiorgan dysfunction are among the leading causes"/>
 <result pre="betacoronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute" exact="respiratory" post="distress syndrome (ARDS) and multiorgan dysfunction are among the"/>
 <result pre="severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress" exact="syndrome" post="(ARDS) and multiorgan dysfunction are among the leading causes"/>
 <result pre="leading causes of death in critically ill patients with COVID-19." exact="Elevated" post="concentrations of proinflammatory cytokines and chemokines including interleukin (IL)-2,"/>
 <result pre="(IL)-2, IL-6, interferon gammaâ€&quot;induced protein 10, macrophage inflammatory protein alpha," exact="monocyte" post="chemotactic protein 1 and tumour necrosis factor-alpha (TNF-Î±) [1,2]"/>
 <result pre="tumour necrosis factor-alpha (TNF-Î±) [1,2] suggest that a cytokine release" exact="syndrome" post="may play a major role in the pathology of"/>
 <result pre="been linked to elderly subjects and those with comorbidities including" exact="pulmonary" post="disease, cardiac disease, kidney disease, diabetes, hypertension and cancer"/>
 <result pre="to elderly subjects and those with comorbidities including pulmonary disease," exact="cardiac disease," post="kidney disease, diabetes, hypertension and cancer [3]. Whether cancer"/>
 <result pre="subjects and those with comorbidities including pulmonary disease, cardiac disease," exact="kidney disease," post="diabetes, hypertension and cancer [3]. Whether cancer per se"/>
 <result pre="with comorbidities including pulmonary disease, cardiac disease, kidney disease, diabetes," exact="hypertension" post="and cancer [3]. Whether cancer per se increases the"/>
 <result pre="including pulmonary disease, cardiac disease, kidney disease, diabetes, hypertension and" exact="cancer" post="[3]. Whether cancer per se increases the risk of"/>
 <result pre="cardiac disease, kidney disease, diabetes, hypertension and cancer [3]. Whether" exact="cancer" post="per se increases the risk of SARS-CoV-2 infection and"/>
 <result pre="[3]. Whether cancer per se increases the risk of SARS-CoV-2" exact="infection" post="and its complications or rather cancer-associated comorbidities and treatment"/>
 <result pre="to be clarified. A recent study showed that patients with" exact="cancer" post="undergoing chemotherapy or surgery in the past month have"/>
 <result pre="[4]. This risk seemed higher in the presence of additional" exact="chronic" post="medical conditions, which is consistent with other recent reports"/>
 <result pre="which are extensively used to treat many cancers. Given the" exact="limited" post="number of cases analysed, these findings could simply be"/>
 <result pre="with COVID-19. While chemotherapies are indeed known to exert a" exact="systemic" post="immunosuppression along with a myelosuppressive state by lowering the"/>
 <result pre="systemic immunosuppression along with a myelosuppressive state by lowering the" exact="complete" post="blood count and/or impairing the immune regulatory response even"/>
 <result pre="reduce organ dysfunctions. T cells play a vital role in" exact="viral" post="clearance, with CD8+ cytotoxic T cells (CTLs) capable of"/>
 <result pre="impaired host immunity accompanied by a significant cell degeneration in" exact="secondary" post="lymphoid tissues follows the initial hyperinflammatory phase of COVID-19."/>
 <result pre="with COVID-19 often present with lymphocytopenia: A fall in the" exact="total" post="lymphocyte number to 0.6Â Ã—Â 106/mL is associated with"/>
 <result pre="PD-1 and T-cell immunoglobulin mucin-3 on the surface of their" exact="peripheral" post="T cells, which in turn impair T-cell effector functions"/>
 <result pre="and prevent functional memory [9]. Finally, compared with cases of" exact="pneumonia" post="not caused by SARS-CoV-2, patients with COVID-19 have decreased"/>
 <result pre="and natural killer cells [10]. These latest data suggest that" exact="viral" post="damage is direct rather than inflammatory driven and strongly"/>
 <result pre="CS. Among immune-activating drugs, ICIs have been recently tested beyond" exact="cancer" post="treatment for their potential to restore immunocompetence in the"/>
 <result pre="A recent phase Ib trial reported that in patients with" exact="systemic" post="sepsis, the antiâ€&quot;PD-1 monoclonal antibody nivolumab can restore lymphocyte"/>
 <result pre="the safety of ICIs was influenza vaccination in patients with" exact="cancer" post="treated with antiâ€&quot;PD-1/antiâ€&quot;PD-L1 antibodies. Several studies reported no increase"/>
 <result pre="immune-related adverse events [13,14], and as an additional finding, a" exact="lower" post="overall rate of influenza among vaccinated patients when compared"/>
 <result pre="[15]. These data suggest that ICIs enhance T-cell response to" exact="viral" post="antigens without triggering unintended immune consequences including the CS"/>
 <result pre="outbreak in China, COVID-19 was empirically treated with antiviral and" exact="respiratory" post="supportive therapies mainly agents already used in prior SARS"/>
 <result pre="plethora of anti-inflammatory agents have been proposed to alleviate the" exact="systemic" post="CS. Based on the promising results from an open-label"/>
 <result pre="IL-6 receptors (IL-6Rs)â€&quot;is currently being investigated to address cytokine release" exact="syndrome" post="in patients with severe ARDS, which includes randomised, controlled"/>
 <result pre="and complementary mechanism. PD-1 expression likely increases to prevent an" exact="uncontrolled" post="inflammatory cascade [17]. Therefore, the use of antiâ€&quot;PD-1 treatment"/>
 <result pre="This approach requires caution. Indeed, in the early phase of" exact="viral infection," post="the PD-1/PD-L1 axis is also involved in the physiological"/>
 <result pre="in HLA alleles have been recently recognised to confer differential" exact="viral" post="susceptibility and severity of COVID-19 [19]. Data validated in"/>
 <result pre="[19]. Data validated in two independent cohorts of patients with" exact="cancer" post="receiving ICIs revealed that heterozygous HLA-I genotypes were associated"/>
 <result pre="highlight that genetic variability in the immune system may affect" exact="susceptibility to" post="(and severity of) SARS-CoV-2; therefore, strategies to boost immune"/>
 <result pre="Wuhan, ChinaLancet39510223202049750610.1016/S0140-6736(20)30183-531986264 2ZhouF.YuT.DuR.FanG.LiuY.LiuZ.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="nationwide analysis in ChinaLancet Oncol213202033533710.1016/S1470-2045(20)30096-632066541 5YuJ.OuyangW.ChuaM.L.K.XieC.SARS-CoV-2 transmission in patients with" exact="cancer" post="at a tertiary care hospital in Wuhan, ChinaJAMA Oncol202010.1001/jamaoncol.2020.0980Published"/>
 <result pre="Wuhan, ChinaJAMA Oncol202010.1001/jamaoncol.2020.0980Published online March 25 6BersanelliM.ScalaS.AffanniP.VeronesiL.ColucciM.E.BannaG.L.Immunological insights on influenza" exact="infection" post="and vaccination during immune checkpoint blockade in cancer patientsImmunotherapy122202010511010.2217/imt-2019-020032046555"/>
 <result pre="on influenza infection and vaccination during immune checkpoint blockade in" exact="cancer" post="patientsImmunotherapy122202010511010.2217/imt-2019-020032046555 7ZhengH.-Y.ZhangM.YangC.-X.ZhangN.WangX.-C.YangX.-P.Elevated exhaustion levels and reduced functional diversity of"/>
 <result pre="exhaustion levels and reduced functional diversity of T cells in" exact="peripheral" post="blood may predict severe progression in COVID-19 patients. Cellular"/>
 <result pre="and functional exhaustion of T cells in patients with coronavirus" exact="disease" post="2019 (COVID-19)MedRxiv202010.1101/2020.02.18.200243642020.02.18.20024364 10ZhengY.HuangZ.YingG.ZhangX.YeW.HuZ.Study of the lymphocyte change between COVID-19"/>
 <result pre="(COVID-19)MedRxiv202010.1101/2020.02.18.200243642020.02.18.20024364 10ZhengY.HuangZ.YingG.ZhangX.YeW.HuZ.Study of the lymphocyte change between COVID-19 and non-COVID-19" exact="pneumonia" post="cases suggesting other factors besides uncontrolled inflammation contributed to"/>
 <result pre="between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides" exact="uncontrolled" post="inflammation contributed to multi-organ injury2020Infectious Diseases (except HIV/AIDS) 11HotchkissR.S.ColstonE.YendeS.CrouserE.D.MartinG.S.AlbertsonT.Immune"/>
 <result pre="suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury2020Infectious" exact="Diseases" post="(except HIV/AIDS) 11HotchkissR.S.ColstonE.YendeS.CrouserE.D.MartinG.S.AlbertsonT.Immune checkpoint inhibition in sepsis: a Phase"/>
 <result pre="(BMS-936559)âˆ—Crit Care Med475201963264210.1097/CCM.000000000000368530747773 13BayleA.KhettabM.LucibelloF.ChamseddineA.N.GoldschmidtV.PerretA.Immunogenicity and safety of influenza vaccination in" exact="cancer" post="patients receiving checkpoint inhibitors targeting PD-1 or PD-L1Ann Oncol202010.1016/j.annonc.2020.03.290"/>
 <result pre="PD-1 or PD-L1Ann Oncol202010.1016/j.annonc.2020.03.290 14ChongC.R.ParkV.J.CohenB.PostowM.A.WolchokJ.D.KambojM.Safety of inactivated influenza vaccine in" exact="cancer" post="patients receiving immune checkpoint inhibitorsClin Infect Dis702202019319910.1093/cid/ciz20230874791 15ChenN.ZhouM.DongX.QuJ.GongF.HanY.Epidemiological and"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet39510223202050751310.1016/S0140-6736(20)30211-732007143 16XuX.HanM.LiT.SunW.WangD.FuB.Effective treatment of"/>
 <result pre="T cell differentiationProc NatlÂ Acad Sci USA1151820184749475410.1073/pnas.171821711529654146 18BillerbeckE.WolfisbergR.FahnÃ¸eU.XiaoJ.W.QuirkC.LunaJ.M.Mouse models of" exact="acute" post="and chronic hepacivirus infectionScience3576347201720420810.1126/science.aal196228706073 19NguyenA.DavidJ.K.MadenS.K.WoodM.A.WeederB.R.NelloreA.Human leukocyte antigen susceptibility map"/>
 <result pre="differentiationProc NatlÂ Acad Sci USA1151820184749475410.1073/pnas.171821711529654146 18BillerbeckE.WolfisbergR.FahnÃ¸eU.XiaoJ.W.QuirkC.LunaJ.M.Mouse models of acute and" exact="chronic" post="hepacivirus infectionScience3576347201720420810.1126/science.aal196228706073 19NguyenA.DavidJ.K.MadenS.K.WoodM.A.WeederB.R.NelloreA.Human leukocyte antigen susceptibility map for SARS-CoV-2J"/>
 <result pre="map for SARS-CoV-2J Virol202010.1128/JVI.00510-20 20ChowellD.MorrisL.G.T.GriggC.M.WeberJ.K.SamsteinR.M.MakarovV.Patient HLA class I genotype influences" exact="cancer" post="response to checkpoint blockade immunotherapyScience3596375201858258710.1126/science.aao457229217585"/>
</results>
